Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday, October 9th, MarketBeat Ratings reports. They presently have a $30.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $20.00. HC Wainwright’s price objective suggests a potential upside of 86.34% from the company’s previous close.
A number of other research firms have also recently weighed in on ABEO. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research report on Friday, October 6th. Royal Bank Of Canada began coverage on shares of Abeona Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective for the company. Maxim Group set a $17.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 29th. BidaskClub upgraded shares of Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 12th. Finally, Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Abeona Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $22.56.
Shares of Abeona Therapeutics (ABEO) opened at 16.10 on Monday. Abeona Therapeutics has a one year low of $4.05 and a one year high of $22.75. The company’s market capitalization is $648.62 million. The firm has a 50-day moving average of $15.53 and a 200-day moving average of $8.77.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. Analysts forecast that Abeona Therapeutics will post ($0.70) earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the last quarter. Ardsley Advisory Partners raised its position in shares of Abeona Therapeutics by 33.3% in the second quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 15,000 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $122,000. Bank of New York Mellon Corp raised its position in shares of Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 23,358 shares during the last quarter. Finally, Family Management Corp acquired a new stake in shares of Abeona Therapeutics in the first quarter valued at about $120,000. Institutional investors and hedge funds own 38.38% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.